Top Markets
Coin of the day
Metsera, Inc. Metsera, Inc.

Metsera, Inc.

MTSR
Classement en actions #2737
Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in... Metsera, Inc. operates as a clinical-stage biotechnology firm, specializing in crafting both injectable and oral nutrient-stimulated hormone analog peptides. These therapeutic compounds are primarily aimed at addressing obesity, overweight conditions, and associated health issues. Its developmental pipeline features MET-097i and MET-233i, both under investigation for treating obesity and overweight patients. Furthermore, Metsera is advancing a potential combination therapy involving MET-233i and MET-097i. The company is also progressing additional drug candidates, including MET-002, MET-224o, MET-067i, and MET-034i, all of which target disorders such as diabetes and obesity. Founded in 2022, Metsera, Inc. maintains its corporate headquarters in New York, New York.
Prix de l'action
$70.50
Dernière synchronisation: 2025-11-14
Capitalisation boursière
$7.33B
Changement (1 jour)
0.00%
Changement (1 an)
116.32%
Pays
US
Échange Metsera, Inc. (MTSR)

Catégorie

Historique du rendement du dividende pour Metsera, Inc. (MTSR)
Le rendement du dividende (TTM) de Metsera, Inc. (symbole boursier : MTSR) au 2026 est : 0
Rendement moyen du dividende sur les 5 dernières années : 0.00%
Historique du rendement du dividende de Metsera, Inc. (MTSR) de 2026 à 2026
Rendement du dividende à la fin de chaque année (TTM)
Année Rendement du dividende Changez
Pas assez de données pour les dates fournies.
Rendements du dividende (TTM) pour des entreprises similaires ou concurrentes
Entreprise Rendement du dividende Pays
0.00%
US
0.00%
NL
0.00%
US
3.12%
AU
0.00%
CH